Review





Similar Products

99
MedChemExpress ampk inhibitor dorsomorphin
Biogenic SeNPs regulated <t>AMPK/NLRP3/Nrf2</t> signaling pathway to alleviate intestinal epithelial barrier oxidative damage in gut-on-a-chip. A. Schematic diagram of experimental design. B. pAMPK/NLRP3/Nrf2 immunofluorescent staining (Scale bar: 40 μm). C. Villi-like height. D. LDH activity in the upper channel layer. E. IL-1β levels in the upper channel layer. F. IL-18 levels in the upper channel layer. G. Schematic diagram of the mechanism by which SeNPs exert antioxidant effects against oxidative damage to intestinal epithelial cells in vitro . Data are expressed as mean ± S.E.M. n = 4. * P < 0.05, ** P < 0.01, *** P < 0.001.
Ampk Inhibitor Dorsomorphin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ampk inhibitor dorsomorphin/product/MedChemExpress
Average 99 stars, based on 1 article reviews
ampk inhibitor dorsomorphin - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier

95
MedChemExpress ampk activator aicar
Biogenic SeNPs regulated <t>AMPK/NLRP3/Nrf2</t> signaling pathway to alleviate intestinal epithelial barrier oxidative damage in gut-on-a-chip. A. Schematic diagram of experimental design. B. pAMPK/NLRP3/Nrf2 immunofluorescent staining (Scale bar: 40 μm). C. Villi-like height. D. LDH activity in the upper channel layer. E. IL-1β levels in the upper channel layer. F. IL-18 levels in the upper channel layer. G. Schematic diagram of the mechanism by which SeNPs exert antioxidant effects against oxidative damage to intestinal epithelial cells in vitro . Data are expressed as mean ± S.E.M. n = 4. * P < 0.05, ** P < 0.01, *** P < 0.001.
Ampk Activator Aicar, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ampk activator aicar/product/MedChemExpress
Average 95 stars, based on 1 article reviews
ampk activator aicar - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

95
MedChemExpress ampk agonist acadesine aicar group
Biogenic SeNPs regulated <t>AMPK/NLRP3/Nrf2</t> signaling pathway to alleviate intestinal epithelial barrier oxidative damage in gut-on-a-chip. A. Schematic diagram of experimental design. B. pAMPK/NLRP3/Nrf2 immunofluorescent staining (Scale bar: 40 μm). C. Villi-like height. D. LDH activity in the upper channel layer. E. IL-1β levels in the upper channel layer. F. IL-18 levels in the upper channel layer. G. Schematic diagram of the mechanism by which SeNPs exert antioxidant effects against oxidative damage to intestinal epithelial cells in vitro . Data are expressed as mean ± S.E.M. n = 4. * P < 0.05, ** P < 0.01, *** P < 0.001.
Ampk Agonist Acadesine Aicar Group, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ampk agonist acadesine aicar group/product/MedChemExpress
Average 95 stars, based on 1 article reviews
ampk agonist acadesine aicar group - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

99
MedChemExpress ampk inhibitor compound c
Gin A activates <t>AMPK</t> and suppresses mTOR/S6K1 signaling in A10 cells (A) Concentration-dependent effects of Gin A on AMPK phosphorylation. A10 cells were treated with Gin A at 0.1, 1, 10 or 100 μM for 24 h, and p-AMPK/AMPK ratios were determined by Western blot. (B) Time course of AMPK activation by Gin A. Cells were exposed to Gin A (10 μM) for 0.5, 1, 3, 6 or 24 h, and p-AMPK/AMPK levels were determined by Western blot. (C) Effects of Gin A on mTOR phosphorylation. A10 cells were treated with Gin A at 0.1, 1, 10 or 100 μM for 24 h, and p-mTOR/mTOR ratios were determined by Western blot. (D) Effects of Gin A on S6K1 phosphorylation. A10 cells were treated with Gin A at 0.1, 1, 10 or 100 μM for 24 h, and p-S6K1/S6K1 ratios determined by Western blot (n = 6; * P < 0.05 vs. control).
Ampk Inhibitor Compound C, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ampk inhibitor compound c/product/MedChemExpress
Average 99 stars, based on 1 article reviews
ampk inhibitor compound c - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier

99
MedChemExpress ampk inhibitor
Gin A activates <t>AMPK</t> and suppresses mTOR/S6K1 signaling in A10 cells (A) Concentration-dependent effects of Gin A on AMPK phosphorylation. A10 cells were treated with Gin A at 0.1, 1, 10 or 100 μM for 24 h, and p-AMPK/AMPK ratios were determined by Western blot. (B) Time course of AMPK activation by Gin A. Cells were exposed to Gin A (10 μM) for 0.5, 1, 3, 6 or 24 h, and p-AMPK/AMPK levels were determined by Western blot. (C) Effects of Gin A on mTOR phosphorylation. A10 cells were treated with Gin A at 0.1, 1, 10 or 100 μM for 24 h, and p-mTOR/mTOR ratios were determined by Western blot. (D) Effects of Gin A on S6K1 phosphorylation. A10 cells were treated with Gin A at 0.1, 1, 10 or 100 μM for 24 h, and p-S6K1/S6K1 ratios determined by Western blot (n = 6; * P < 0.05 vs. control).
Ampk Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ampk inhibitor/product/MedChemExpress
Average 99 stars, based on 1 article reviews
ampk inhibitor - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier

95
Proteintech ampk
CMSP <t>reduces</t> <t>AMPK/mTOR</t> pathway activity in ESCC cells. (A) AMP, ATP, and ratio of AMP and ATP response to CMSP treatment in targeted metabolomics. (B) Representative Western blot of p-mTOR, mTOR, p-AMPK, AMPK, p-P70S6K, P70S6K, p-ULK1, and ULK1 following treatment of concentration-dependent CMSP for 36 h. (C) Representative Western blot of p-mTOR, p-AMPK, p-P70S6K, and p-ULK1 following treatment of CMSP (40 μg/ml) for different time. (D) Representative Western blot of p-mTOR, p-AMPK, p-P70S6K and p-ULK1 following treatment of CMSP (40 μg/ml) and rapamycin (20 nM). Data are shown as the mean ± SD ( n = 3); Student’s t test; ** P < 0.01 versus the control group.
Ampk, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ampk/product/Proteintech
Average 95 stars, based on 1 article reviews
ampk - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

95
Proteintech ampk2 protein
CMSP <t>reduces</t> <t>AMPK/mTOR</t> pathway activity in ESCC cells. (A) AMP, ATP, and ratio of AMP and ATP response to CMSP treatment in targeted metabolomics. (B) Representative Western blot of p-mTOR, mTOR, p-AMPK, AMPK, p-P70S6K, P70S6K, p-ULK1, and ULK1 following treatment of concentration-dependent CMSP for 36 h. (C) Representative Western blot of p-mTOR, p-AMPK, p-P70S6K, and p-ULK1 following treatment of CMSP (40 μg/ml) for different time. (D) Representative Western blot of p-mTOR, p-AMPK, p-P70S6K and p-ULK1 following treatment of CMSP (40 μg/ml) and rapamycin (20 nM). Data are shown as the mean ± SD ( n = 3); Student’s t test; ** P < 0.01 versus the control group.
Ampk2 Protein, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ampk2 protein/product/Proteintech
Average 95 stars, based on 1 article reviews
ampk2 protein - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

95
Proteintech ampkα
AYN activated <t>AMPKα</t> pathway in tissues. (A) AYN intervention increased p‐AMPKα, GLUT4, and CPT‐1α expression in epWAT; (B) Relative band intensity <t>for</t> <t>GLUT4/β‐Actin,</t> CPT‐1α/β‐Actin, p‐AMPKα/AMPKα for protein in epWAT; (C) AYN intervention increased p‐AMPKα, GLUT4, and CPT‐1α expression in skeletal muscles; (D) Relative band intensity for GLUT4/β‐Actin, CPT‐1α/β‐Actin, p‐AMPKα/AMPKα for protein in skeletal muscles. (E) AYN intervention increased p‐AMPKα and CPT‐1α expression in livers; (F) Relative band intensity for CPT‐1α/β‐Actin, p‐AMPKα/AMPKα for protein in livers. ( n = 3, +++ p < 0.001, compared with Normal control group; * p < 0.05, ** p < 0.01, *** p < 0.001, compared with Vehicle control group).
Ampkα, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ampkα/product/Proteintech
Average 95 stars, based on 1 article reviews
ampkα - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

95
Proteintech p ampkα
AYN activated <t>AMPKα</t> pathway in tissues. (A) AYN intervention increased p‐AMPKα, GLUT4, and CPT‐1α expression in epWAT; (B) Relative band intensity <t>for</t> <t>GLUT4/β‐Actin,</t> CPT‐1α/β‐Actin, p‐AMPKα/AMPKα for protein in epWAT; (C) AYN intervention increased p‐AMPKα, GLUT4, and CPT‐1α expression in skeletal muscles; (D) Relative band intensity for GLUT4/β‐Actin, CPT‐1α/β‐Actin, p‐AMPKα/AMPKα for protein in skeletal muscles. (E) AYN intervention increased p‐AMPKα and CPT‐1α expression in livers; (F) Relative band intensity for CPT‐1α/β‐Actin, p‐AMPKα/AMPKα for protein in livers. ( n = 3, +++ p < 0.001, compared with Normal control group; * p < 0.05, ** p < 0.01, *** p < 0.001, compared with Vehicle control group).
P Ampkα, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p ampkα/product/Proteintech
Average 95 stars, based on 1 article reviews
p ampkα - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

96
Proteintech protein kinase ampk polyclonal antibody
AYN activated <t>AMPKα</t> pathway in tissues. (A) AYN intervention increased p‐AMPKα, GLUT4, and CPT‐1α expression in epWAT; (B) Relative band intensity <t>for</t> <t>GLUT4/β‐Actin,</t> CPT‐1α/β‐Actin, p‐AMPKα/AMPKα for protein in epWAT; (C) AYN intervention increased p‐AMPKα, GLUT4, and CPT‐1α expression in skeletal muscles; (D) Relative band intensity for GLUT4/β‐Actin, CPT‐1α/β‐Actin, p‐AMPKα/AMPKα for protein in skeletal muscles. (E) AYN intervention increased p‐AMPKα and CPT‐1α expression in livers; (F) Relative band intensity for CPT‐1α/β‐Actin, p‐AMPKα/AMPKα for protein in livers. ( n = 3, +++ p < 0.001, compared with Normal control group; * p < 0.05, ** p < 0.01, *** p < 0.001, compared with Vehicle control group).
Protein Kinase Ampk Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/protein kinase ampk polyclonal antibody/product/Proteintech
Average 96 stars, based on 1 article reviews
protein kinase ampk polyclonal antibody - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

Image Search Results


Biogenic SeNPs regulated AMPK/NLRP3/Nrf2 signaling pathway to alleviate intestinal epithelial barrier oxidative damage in gut-on-a-chip. A. Schematic diagram of experimental design. B. pAMPK/NLRP3/Nrf2 immunofluorescent staining (Scale bar: 40 μm). C. Villi-like height. D. LDH activity in the upper channel layer. E. IL-1β levels in the upper channel layer. F. IL-18 levels in the upper channel layer. G. Schematic diagram of the mechanism by which SeNPs exert antioxidant effects against oxidative damage to intestinal epithelial cells in vitro . Data are expressed as mean ± S.E.M. n = 4. * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: Journal of Advanced Research

Article Title: Prophylactic supplementation with biogenic selenium nanoparticles mitigated intestinal barrier oxidative damage through suppressing epithelial-immune crosstalk with gut-on-a-chip

doi: 10.1016/j.jare.2025.04.023

Figure Lengend Snippet: Biogenic SeNPs regulated AMPK/NLRP3/Nrf2 signaling pathway to alleviate intestinal epithelial barrier oxidative damage in gut-on-a-chip. A. Schematic diagram of experimental design. B. pAMPK/NLRP3/Nrf2 immunofluorescent staining (Scale bar: 40 μm). C. Villi-like height. D. LDH activity in the upper channel layer. E. IL-1β levels in the upper channel layer. F. IL-18 levels in the upper channel layer. G. Schematic diagram of the mechanism by which SeNPs exert antioxidant effects against oxidative damage to intestinal epithelial cells in vitro . Data are expressed as mean ± S.E.M. n = 4. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: To investigate the role of the AMPK signaling pathway in the protection of the intestinal epithelial barrier from oxidative stress damage by SeNPs, AMPK activator AICAR (MedChemExpres; Cat# HY-13417) and AMPK inhibitor Dorsomorphin (MedChemExpres; Cat# HY-13418A) were introduced into the gut-on-a-chip, respectively.

Techniques: Staining, Activity Assay, In Vitro

Biogenic SeNPs regulated AMPK/NLRP3/Nrf2 signaling pathway to attenuate oxidative stress-induced intestinal barrier dysfunction and mast cell overactivation in mice. A. Immunofluorescence analysis of p-AMPK (red), NLRP3 (yellow) and Nrf2 (green) in jejunum of mice with different treatments (Scale bar: 100 μm). B. Western blot analysis of pAMPK and Nrf2 expression levels in mice jejunum. C. Western blot analysis of NLRP3 and its downstream pyroptosis-related protein expression levels in mice jejunum. Data are expressed as mean ± S.E.M. n = 3. * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: Journal of Advanced Research

Article Title: Prophylactic supplementation with biogenic selenium nanoparticles mitigated intestinal barrier oxidative damage through suppressing epithelial-immune crosstalk with gut-on-a-chip

doi: 10.1016/j.jare.2025.04.023

Figure Lengend Snippet: Biogenic SeNPs regulated AMPK/NLRP3/Nrf2 signaling pathway to attenuate oxidative stress-induced intestinal barrier dysfunction and mast cell overactivation in mice. A. Immunofluorescence analysis of p-AMPK (red), NLRP3 (yellow) and Nrf2 (green) in jejunum of mice with different treatments (Scale bar: 100 μm). B. Western blot analysis of pAMPK and Nrf2 expression levels in mice jejunum. C. Western blot analysis of NLRP3 and its downstream pyroptosis-related protein expression levels in mice jejunum. Data are expressed as mean ± S.E.M. n = 3. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: To investigate the role of the AMPK signaling pathway in the protection of the intestinal epithelial barrier from oxidative stress damage by SeNPs, AMPK activator AICAR (MedChemExpres; Cat# HY-13417) and AMPK inhibitor Dorsomorphin (MedChemExpres; Cat# HY-13418A) were introduced into the gut-on-a-chip, respectively.

Techniques: Immunofluorescence, Western Blot, Expressing

Biogenic SeNPs regulated AMPK/NLRP3/Nrf2 signaling pathway to alleviate intestinal epithelial barrier oxidative damage in gut-on-a-chip. A. Schematic diagram of experimental design. B. pAMPK/NLRP3/Nrf2 immunofluorescent staining (Scale bar: 40 μm). C. Villi-like height. D. LDH activity in the upper channel layer. E. IL-1β levels in the upper channel layer. F. IL-18 levels in the upper channel layer. G. Schematic diagram of the mechanism by which SeNPs exert antioxidant effects against oxidative damage to intestinal epithelial cells in vitro . Data are expressed as mean ± S.E.M. n = 4. * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: Journal of Advanced Research

Article Title: Prophylactic supplementation with biogenic selenium nanoparticles mitigated intestinal barrier oxidative damage through suppressing epithelial-immune crosstalk with gut-on-a-chip

doi: 10.1016/j.jare.2025.04.023

Figure Lengend Snippet: Biogenic SeNPs regulated AMPK/NLRP3/Nrf2 signaling pathway to alleviate intestinal epithelial barrier oxidative damage in gut-on-a-chip. A. Schematic diagram of experimental design. B. pAMPK/NLRP3/Nrf2 immunofluorescent staining (Scale bar: 40 μm). C. Villi-like height. D. LDH activity in the upper channel layer. E. IL-1β levels in the upper channel layer. F. IL-18 levels in the upper channel layer. G. Schematic diagram of the mechanism by which SeNPs exert antioxidant effects against oxidative damage to intestinal epithelial cells in vitro . Data are expressed as mean ± S.E.M. n = 4. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: To investigate the role of the AMPK signaling pathway in the protection of the intestinal epithelial barrier from oxidative stress damage by SeNPs, AMPK activator AICAR (MedChemExpres; Cat# HY-13417) and AMPK inhibitor Dorsomorphin (MedChemExpres; Cat# HY-13418A) were introduced into the gut-on-a-chip, respectively.

Techniques: Staining, Activity Assay, In Vitro

Biogenic SeNPs regulated AMPK/NLRP3/Nrf2 signaling pathway to attenuate oxidative stress-induced intestinal barrier dysfunction and mast cell overactivation in mice. A. Immunofluorescence analysis of p-AMPK (red), NLRP3 (yellow) and Nrf2 (green) in jejunum of mice with different treatments (Scale bar: 100 μm). B. Western blot analysis of pAMPK and Nrf2 expression levels in mice jejunum. C. Western blot analysis of NLRP3 and its downstream pyroptosis-related protein expression levels in mice jejunum. Data are expressed as mean ± S.E.M. n = 3. * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: Journal of Advanced Research

Article Title: Prophylactic supplementation with biogenic selenium nanoparticles mitigated intestinal barrier oxidative damage through suppressing epithelial-immune crosstalk with gut-on-a-chip

doi: 10.1016/j.jare.2025.04.023

Figure Lengend Snippet: Biogenic SeNPs regulated AMPK/NLRP3/Nrf2 signaling pathway to attenuate oxidative stress-induced intestinal barrier dysfunction and mast cell overactivation in mice. A. Immunofluorescence analysis of p-AMPK (red), NLRP3 (yellow) and Nrf2 (green) in jejunum of mice with different treatments (Scale bar: 100 μm). B. Western blot analysis of pAMPK and Nrf2 expression levels in mice jejunum. C. Western blot analysis of NLRP3 and its downstream pyroptosis-related protein expression levels in mice jejunum. Data are expressed as mean ± S.E.M. n = 3. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: To investigate the role of the AMPK signaling pathway in the protection of the intestinal epithelial barrier from oxidative stress damage by SeNPs, AMPK activator AICAR (MedChemExpres; Cat# HY-13417) and AMPK inhibitor Dorsomorphin (MedChemExpres; Cat# HY-13418A) were introduced into the gut-on-a-chip, respectively.

Techniques: Immunofluorescence, Western Blot, Expressing

Gin A activates AMPK and suppresses mTOR/S6K1 signaling in A10 cells (A) Concentration-dependent effects of Gin A on AMPK phosphorylation. A10 cells were treated with Gin A at 0.1, 1, 10 or 100 μM for 24 h, and p-AMPK/AMPK ratios were determined by Western blot. (B) Time course of AMPK activation by Gin A. Cells were exposed to Gin A (10 μM) for 0.5, 1, 3, 6 or 24 h, and p-AMPK/AMPK levels were determined by Western blot. (C) Effects of Gin A on mTOR phosphorylation. A10 cells were treated with Gin A at 0.1, 1, 10 or 100 μM for 24 h, and p-mTOR/mTOR ratios were determined by Western blot. (D) Effects of Gin A on S6K1 phosphorylation. A10 cells were treated with Gin A at 0.1, 1, 10 or 100 μM for 24 h, and p-S6K1/S6K1 ratios determined by Western blot (n = 6; * P < 0.05 vs. control).

Journal: Frontiers in Pharmacology

Article Title: Gingerenone A attenuates diabetic vascular remodeling through AMPK/mTOR/S6K1 signaling

doi: 10.3389/fphar.2026.1706103

Figure Lengend Snippet: Gin A activates AMPK and suppresses mTOR/S6K1 signaling in A10 cells (A) Concentration-dependent effects of Gin A on AMPK phosphorylation. A10 cells were treated with Gin A at 0.1, 1, 10 or 100 μM for 24 h, and p-AMPK/AMPK ratios were determined by Western blot. (B) Time course of AMPK activation by Gin A. Cells were exposed to Gin A (10 μM) for 0.5, 1, 3, 6 or 24 h, and p-AMPK/AMPK levels were determined by Western blot. (C) Effects of Gin A on mTOR phosphorylation. A10 cells were treated with Gin A at 0.1, 1, 10 or 100 μM for 24 h, and p-mTOR/mTOR ratios were determined by Western blot. (D) Effects of Gin A on S6K1 phosphorylation. A10 cells were treated with Gin A at 0.1, 1, 10 or 100 μM for 24 h, and p-S6K1/S6K1 ratios determined by Western blot (n = 6; * P < 0.05 vs. control).

Article Snippet: A10 cells were co-treated with Gin A and the pharmacological AMPK inhibitor Compound C (HY-13418A, MCE, United States) under HG (30 mM) stimulation.

Techniques: Concentration Assay, Phospho-proteomics, Western Blot, Activation Assay, Control

Role of AMPK activation in the Gin A-mediated inhibition of the proliferation and migration of HG-treated A10 cells (A) Effect of the AMPK inhibitor Compound C on Gin A-induced AMPK activation in HG-treated A10 cells. Cells were pre-incubated with Compound C for 1 h and then exposed to HG (30 mM) with or without Gin A (10 μM) for 24 h. Representative blots and p-AMPK/AMPK ratios are shown (n = 6; * P < 0.05 vs. control; # P < 0.05 vs. Gin A alone). (B–D) Effects of Compound C on the Gin A-induced inhibition of A10 cell proliferation and migration. Cell proliferation was determined by the MTT assay (B) . Cell migration was determined by Transwell (C) and wound healing (D) assays (n = 8; * P < 0.05 vs. control; # P < 0.05 vs. HG alone; & P < 0.05 vs. HG + Gin A). (E,F) Effects of Compound C on Gin A-mediated inhibition of mTOR/S6K1 signaling in HG-treated A10 cells. Representative blots and quantification of p-mTOR/mTOR (E) and p-S6K1/S6K1 (F) ratios are shown (n = 6; * P < 0.05 vs. control; # P < 0.05 vs. HG alone; & P < 0.05 vs. HG + Gin A).

Journal: Frontiers in Pharmacology

Article Title: Gingerenone A attenuates diabetic vascular remodeling through AMPK/mTOR/S6K1 signaling

doi: 10.3389/fphar.2026.1706103

Figure Lengend Snippet: Role of AMPK activation in the Gin A-mediated inhibition of the proliferation and migration of HG-treated A10 cells (A) Effect of the AMPK inhibitor Compound C on Gin A-induced AMPK activation in HG-treated A10 cells. Cells were pre-incubated with Compound C for 1 h and then exposed to HG (30 mM) with or without Gin A (10 μM) for 24 h. Representative blots and p-AMPK/AMPK ratios are shown (n = 6; * P < 0.05 vs. control; # P < 0.05 vs. Gin A alone). (B–D) Effects of Compound C on the Gin A-induced inhibition of A10 cell proliferation and migration. Cell proliferation was determined by the MTT assay (B) . Cell migration was determined by Transwell (C) and wound healing (D) assays (n = 8; * P < 0.05 vs. control; # P < 0.05 vs. HG alone; & P < 0.05 vs. HG + Gin A). (E,F) Effects of Compound C on Gin A-mediated inhibition of mTOR/S6K1 signaling in HG-treated A10 cells. Representative blots and quantification of p-mTOR/mTOR (E) and p-S6K1/S6K1 (F) ratios are shown (n = 6; * P < 0.05 vs. control; # P < 0.05 vs. HG alone; & P < 0.05 vs. HG + Gin A).

Article Snippet: A10 cells were co-treated with Gin A and the pharmacological AMPK inhibitor Compound C (HY-13418A, MCE, United States) under HG (30 mM) stimulation.

Techniques: Activation Assay, Inhibition, Migration, Incubation, Control, MTT Assay

Experimental validation in primary HASMCs with siRNA knockdown and osmotic stress controls (A) Confirmation of AMPK knockdown in primary HASMCs. Representative western blots and AMPK/GAPDH ratios in scrambled siRNA- and AMPK siRNA-transfected cells are shown (n = 6; * P < 0.05 vs. control). (B) Effects of Gin A (10 μM) and AMPK knockdown on AMPK phosphorylation in HASMCs exposed to HG (25 mM) for 24 h. Representative blots and p-AMPK/GAPDH ratios are shown (n = 6; * P < 0.05 vs. control; # P < 0.05 vs. si-AMPK alone; & P < 0.05 vs. si-AMPK + Gin A). (C) Effects of Gin A and AMPK knockdown on HG-induced HASMC proliferation. Cells were exposed to normal glucose or HG (25 mM) with or without Gin A (10 μM) and with scrambled or AMPK-targeting siRNA, and proliferation was measured by MTT assay (n = 6; * P < 0.05 vs. normal-glucose control; # P < 0.05 vs. HG alone; & P < 0.05 vs. HG + Gin A with scrambled siRNA). (D) Osmotic control experiments in HASMCs. Cells were cultured for 24 h in normal glucose (5.5 mM), HG (25 mM), L-glucose (25 mM) or D-mannitol (25 mM), and proliferation was assessed by MTT assay (n = 6; * P < 0.05 vs. normal-glucose control).

Journal: Frontiers in Pharmacology

Article Title: Gingerenone A attenuates diabetic vascular remodeling through AMPK/mTOR/S6K1 signaling

doi: 10.3389/fphar.2026.1706103

Figure Lengend Snippet: Experimental validation in primary HASMCs with siRNA knockdown and osmotic stress controls (A) Confirmation of AMPK knockdown in primary HASMCs. Representative western blots and AMPK/GAPDH ratios in scrambled siRNA- and AMPK siRNA-transfected cells are shown (n = 6; * P < 0.05 vs. control). (B) Effects of Gin A (10 μM) and AMPK knockdown on AMPK phosphorylation in HASMCs exposed to HG (25 mM) for 24 h. Representative blots and p-AMPK/GAPDH ratios are shown (n = 6; * P < 0.05 vs. control; # P < 0.05 vs. si-AMPK alone; & P < 0.05 vs. si-AMPK + Gin A). (C) Effects of Gin A and AMPK knockdown on HG-induced HASMC proliferation. Cells were exposed to normal glucose or HG (25 mM) with or without Gin A (10 μM) and with scrambled or AMPK-targeting siRNA, and proliferation was measured by MTT assay (n = 6; * P < 0.05 vs. normal-glucose control; # P < 0.05 vs. HG alone; & P < 0.05 vs. HG + Gin A with scrambled siRNA). (D) Osmotic control experiments in HASMCs. Cells were cultured for 24 h in normal glucose (5.5 mM), HG (25 mM), L-glucose (25 mM) or D-mannitol (25 mM), and proliferation was assessed by MTT assay (n = 6; * P < 0.05 vs. normal-glucose control).

Article Snippet: A10 cells were co-treated with Gin A and the pharmacological AMPK inhibitor Compound C (HY-13418A, MCE, United States) under HG (30 mM) stimulation.

Techniques: Biomarker Discovery, Knockdown, Western Blot, Transfection, Control, Phospho-proteomics, MTT Assay, Cell Culture

Gin A attenuates neointimal hyperplasia and restores AMPK activation in diabetic rats after carotid balloon injury (A) Representative H&E-stained cross-sections of carotid arteries from Sham, Vehicle and Gin A-treated diabetic rats 2 weeks after balloon injury (or sham operation). (B) Quantitative analysis of the intima-to-media (I/M) ratio in carotid arteries from the indicated groups. (C) Effects of Gin A on PCNA expression levels in carotid arteries of diabetic rats. Representative western blots and PCNA/H3 ratios are shown. (D,E) Effects of Gin A on oxidative stress markers in carotid arteries of diabetic rats. MDA (D) and T-AOC (E) measured in vascular tissue lysates. (F) Effects of Gin A on AMPK activation in carotid arteries of diabetic rats. Representative western blots and quantification of p-AMPK/AMPK ratios in carotid arteries are shown, indicating the restoration of AMPK activation by Gin A (n = 6; * P < 0.05 vs. Sham; # P < 0.05 vs. Vehicle).

Journal: Frontiers in Pharmacology

Article Title: Gingerenone A attenuates diabetic vascular remodeling through AMPK/mTOR/S6K1 signaling

doi: 10.3389/fphar.2026.1706103

Figure Lengend Snippet: Gin A attenuates neointimal hyperplasia and restores AMPK activation in diabetic rats after carotid balloon injury (A) Representative H&E-stained cross-sections of carotid arteries from Sham, Vehicle and Gin A-treated diabetic rats 2 weeks after balloon injury (or sham operation). (B) Quantitative analysis of the intima-to-media (I/M) ratio in carotid arteries from the indicated groups. (C) Effects of Gin A on PCNA expression levels in carotid arteries of diabetic rats. Representative western blots and PCNA/H3 ratios are shown. (D,E) Effects of Gin A on oxidative stress markers in carotid arteries of diabetic rats. MDA (D) and T-AOC (E) measured in vascular tissue lysates. (F) Effects of Gin A on AMPK activation in carotid arteries of diabetic rats. Representative western blots and quantification of p-AMPK/AMPK ratios in carotid arteries are shown, indicating the restoration of AMPK activation by Gin A (n = 6; * P < 0.05 vs. Sham; # P < 0.05 vs. Vehicle).

Article Snippet: A10 cells were co-treated with Gin A and the pharmacological AMPK inhibitor Compound C (HY-13418A, MCE, United States) under HG (30 mM) stimulation.

Techniques: Activation Assay, Staining, Expressing, Western Blot

CMSP reduces AMPK/mTOR pathway activity in ESCC cells. (A) AMP, ATP, and ratio of AMP and ATP response to CMSP treatment in targeted metabolomics. (B) Representative Western blot of p-mTOR, mTOR, p-AMPK, AMPK, p-P70S6K, P70S6K, p-ULK1, and ULK1 following treatment of concentration-dependent CMSP for 36 h. (C) Representative Western blot of p-mTOR, p-AMPK, p-P70S6K, and p-ULK1 following treatment of CMSP (40 μg/ml) for different time. (D) Representative Western blot of p-mTOR, p-AMPK, p-P70S6K and p-ULK1 following treatment of CMSP (40 μg/ml) and rapamycin (20 nM). Data are shown as the mean ± SD ( n = 3); Student’s t test; ** P < 0.01 versus the control group.

Journal: Research

Article Title: A Novel Autophagy Inhibitor p -Hydroxylcinnamaldehyde Suppresses Esophageal Squamous Cell Carcinoma by Targeting LDHA Phosphorylation-Mediated Metabolic Reprogramming

doi: 10.34133/research.1070

Figure Lengend Snippet: CMSP reduces AMPK/mTOR pathway activity in ESCC cells. (A) AMP, ATP, and ratio of AMP and ATP response to CMSP treatment in targeted metabolomics. (B) Representative Western blot of p-mTOR, mTOR, p-AMPK, AMPK, p-P70S6K, P70S6K, p-ULK1, and ULK1 following treatment of concentration-dependent CMSP for 36 h. (C) Representative Western blot of p-mTOR, p-AMPK, p-P70S6K, and p-ULK1 following treatment of CMSP (40 μg/ml) for different time. (D) Representative Western blot of p-mTOR, p-AMPK, p-P70S6K and p-ULK1 following treatment of CMSP (40 μg/ml) and rapamycin (20 nM). Data are shown as the mean ± SD ( n = 3); Student’s t test; ** P < 0.01 versus the control group.

Article Snippet: Antibodies against actin (20536-1-AP), LC3B (14600-1-AP), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (10494-1-AP), p-mTOR (67778-1-Ig), mTOR (66888-1-Ig), AMPK (66536-1-Ig), P70S6K (14485-1-AP), and ULK1 (20986-1-AP) were purchased from Proteintech Group (Wuhan, China).

Techniques: Activity Assay, Western Blot, Concentration Assay, Control

AYN activated AMPKα pathway in tissues. (A) AYN intervention increased p‐AMPKα, GLUT4, and CPT‐1α expression in epWAT; (B) Relative band intensity for GLUT4/β‐Actin, CPT‐1α/β‐Actin, p‐AMPKα/AMPKα for protein in epWAT; (C) AYN intervention increased p‐AMPKα, GLUT4, and CPT‐1α expression in skeletal muscles; (D) Relative band intensity for GLUT4/β‐Actin, CPT‐1α/β‐Actin, p‐AMPKα/AMPKα for protein in skeletal muscles. (E) AYN intervention increased p‐AMPKα and CPT‐1α expression in livers; (F) Relative band intensity for CPT‐1α/β‐Actin, p‐AMPKα/AMPKα for protein in livers. ( n = 3, +++ p < 0.001, compared with Normal control group; * p < 0.05, ** p < 0.01, *** p < 0.001, compared with Vehicle control group).

Journal: Food Science & Nutrition

Article Title: Anti‐Diabetic Effects of Ayanin, a Flavonoid Compound, in STZ / HFD ‐Induced Diabetic Mice by Upregulating GLUT4 and Suppressing Macrophage‐Driven Inflammation in Adipose Tissues

doi: 10.1002/fsn3.71429

Figure Lengend Snippet: AYN activated AMPKα pathway in tissues. (A) AYN intervention increased p‐AMPKα, GLUT4, and CPT‐1α expression in epWAT; (B) Relative band intensity for GLUT4/β‐Actin, CPT‐1α/β‐Actin, p‐AMPKα/AMPKα for protein in epWAT; (C) AYN intervention increased p‐AMPKα, GLUT4, and CPT‐1α expression in skeletal muscles; (D) Relative band intensity for GLUT4/β‐Actin, CPT‐1α/β‐Actin, p‐AMPKα/AMPKα for protein in skeletal muscles. (E) AYN intervention increased p‐AMPKα and CPT‐1α expression in livers; (F) Relative band intensity for CPT‐1α/β‐Actin, p‐AMPKα/AMPKα for protein in livers. ( n = 3, +++ p < 0.001, compared with Normal control group; * p < 0.05, ** p < 0.01, *** p < 0.001, compared with Vehicle control group).

Article Snippet: Antibodies of β‐actin, GLUT4, Cpt‐1α, AMPKα, p‐AMPKα and corresponding secondary antibodies were purchased from Proteintech Group (Wuhan, China).

Techniques: Expressing, Muscles, Control

AYN increased glucose uptake of 3T3‐L1 adipocytes by activating AMPKα/GLUT4 pathway. (A) AYN increased GLUT4 and p‐AMPKα expression in 3T3‐L1 adipocytes; (B) Relative band intensity for GLUT4/β‐Actin, p‐AMPKα/AMPKα for protein in 3T3‐L1 adipocytes; (C) AYN increased the glucose uptake of 3T3‐L1 adipocytes; (D) AMPKα inhibitor, Compound C, suppressed the GLUT4 expression of 3T3‐L1 adipocytes induced by AYN; (E) Compound C inhibited the glucose uptake of 3T3‐L1 adipocytes induced by AYN. ( n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, compared with Normal control group; +++ p < 0.001, compared with AYN group in E).

Journal: Food Science & Nutrition

Article Title: Anti‐Diabetic Effects of Ayanin, a Flavonoid Compound, in STZ / HFD ‐Induced Diabetic Mice by Upregulating GLUT4 and Suppressing Macrophage‐Driven Inflammation in Adipose Tissues

doi: 10.1002/fsn3.71429

Figure Lengend Snippet: AYN increased glucose uptake of 3T3‐L1 adipocytes by activating AMPKα/GLUT4 pathway. (A) AYN increased GLUT4 and p‐AMPKα expression in 3T3‐L1 adipocytes; (B) Relative band intensity for GLUT4/β‐Actin, p‐AMPKα/AMPKα for protein in 3T3‐L1 adipocytes; (C) AYN increased the glucose uptake of 3T3‐L1 adipocytes; (D) AMPKα inhibitor, Compound C, suppressed the GLUT4 expression of 3T3‐L1 adipocytes induced by AYN; (E) Compound C inhibited the glucose uptake of 3T3‐L1 adipocytes induced by AYN. ( n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, compared with Normal control group; +++ p < 0.001, compared with AYN group in E).

Article Snippet: Antibodies of β‐actin, GLUT4, Cpt‐1α, AMPKα, p‐AMPKα and corresponding secondary antibodies were purchased from Proteintech Group (Wuhan, China).

Techniques: Expressing, Control